Please login to the form below
long-term condition
This page shows the latest long-term condition news and features for those working in and with pharma, biotech and healthcare.
Boehringer and Lilly’s Jardiance granted MHRA approval to treat chronic kidney disease
Approximately 7.2 million people in the UK are affected by the long-term kidney condition. ... Approximately 7.2 million people in the UK are affected by CKD, a long-term condition characterised by a gradual loss of kidney function.
Latest news
-
Vironix and Oxford University partner to advance chronic kidney disease monitoring
CKD is a long term condition that progressively causes the kidneys to stop working effectively.
-
NHS England to offer millions of children flu vaccines from September
School-aged children will receive the flu vaccine either at school or at community clinics, and those who are aged two and three years or have long-term health condition will
-
AbbVie doses first patient in phase 3 study of Rinvoq in hidradenitis suppurativa
The long-term inflammatory skin condition affects an estimated 1% of the global population. ... HS is a long-term skin condition that causes painful bumps, nodules or abscesses that can leak fluid and lead to scarring.
-
Eli Lilly and Boehringer’s Jardiance granted EC approval to treat chronic kidney disease
Approximately 47 million people in the EU are affected by the long-term kidney condition. ... Approximately 47 million people in the EU are affected by CKD, a long-term condition characterised by a gradual loss of kidney function.
-
Gilead’s COVID-19 treatment approved by FDA for patients with severe renal impairment
More than 37 million people in the US are estimated to have chronic kidney disease (CKD), a long-term condition characterised by a gradual loss of kidney function.
More from news
Approximately 0 fully matching, plus 39 partially matching documents found.
Latest Intelligence
-
LifeArc’s challenge to combat bronchiectasis
What causes bronchiectasis? Bronchiectasis is a devastating, life-limiting, long-term condition that causes excess mucus build-up in the lungs, increasing the risk of infection and permanent lung damage. ... Bronchiectasis has been increasingly
-
Building a brighter future with patient support programmes
Most of the time they are living with or managing their long-term condition alone, so there is a real opportunity for programmes to provide support for the 363 days a ... PSPs will continue to grow and those that listen to patients from the start,
-
Taking centre stage: the role of behaviour change initiatives in the management of long-term conditions
Knowing what patients struggle with and what drives their health behaviour is crucial in identifying how best to support them in managing their condition. ... Take a 360 view: when people lack resources, they focus their attention on immediate needs and
-
How can pharma better engage and empower patients who are socially disadvantaged?
have a long-term health condition than those who are the least disadvantaged. ... Pharma has long been the driver of health education campaigns, either themselves or in partnership with patient associations.
-
Behavioural science in 2030
A report published by the World Health Organization in 2003 concluded that between a third and a half of medicines prescribed for long-term conditions are not taken as directed. ... Each individual being treated for a long-term condition will receive a
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest from PMHub
-
How can compelling healthcare communications support HCPs with their pandemic patient backlog?
Find out. 1. What the biggest impact has been on long-term condition management in relation to COVID-19.
-
Covid-19 drives change in long-term conditions management
The Long-term Plan said that for ‘many health conditions, people are already taking more control supplemented with expert advice and peer support in the community and online’. ... In common with many other long-term condition patients, people with
-
New local NHS models help to deliver integrated care
Engaging with key stakeholders in neighbourhoods. As more care is provided via neighbourhoods, and hospital outpatients’ departments become less important for ongoing long-term condition management, local NHS staffing roles are ... reducing their
-
How can pharma engage with key stakeholders on NHS service transformation?
Introduction. There is a real drive for change within the NHS to ensure its sustainability in the long-term. ... NHS RightCare provides examples of this with its long-term condition scenarios, such as ‘Susan’s Story: Osteoporosis’, where costs are
-
The role of digital technology in changing patient behaviour
For example, each patient prescribed treatment for a long-term condition will have his own personal set of perceptual and practical barriers to achieving optimal adherence and these can be defined
More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
Kardex
Kardex is a global industry partner for intralogistics solutions and a leading supplier of automated storage solutions and material handling...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
